Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/02—Bacterial antigens
  • A61K39/025—Enterobacteriales, e.g. Enterobacter
  • A61K39/0275—Salmonella
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
  • A61K2039/541—Mucosal route
  • A61K2039/542—Mucosal route oral/gastrointestinal
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
  • A61K2039/552—Veterinary vaccine
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the patent claims a protection of a live attenuated strain of Salmonella enterica CAPM 6449 with specific deletions used for its attenuation, and which is suitable for oral immunisation and protection of farm animals against Salmonella infection.
• the first attenuated vaccines were obtained by prolonged subcultures in vitro or random mutagenesis induced by physical or chemical agents. Such experimental approaches resulted in a selection of strains with reduced virulence but retained immunogenicity. Although such vaccines are fully functional and have been extensively characterised, the real reason of their reduced virulence and attenuation is unknown (Guzman et al., 2006, Vaccine 24, 3804-11 ; Smith 956, J Hyg.(Lond);54, 419-32).
• vaccine strains attenuated by two independent mutations have been tested. These include vaccines with inactivated htrA and aroA genes (Tacket a Levine 2007, Clin. Infect. Dis. 45, S20), or phoP and rpoS genes (Methner et al. 2004, Vet. Microbiol. 98, 37-43).
• ii) is highly immunogenic (Ion mutation results in an overproduction of capsular polysaccharides, SPI1 mutants do not induce cell death in macrophages)
• iii) strains with this combination of mutations can be easily differentiated from wild type Salmonella enterica strains as the strain forms mucoid colonies on common nutrient agars
• the attenuated strain of Salmonella enterica CAPM 6449 was constructed by lambda red recombination. Individual mutations, i.e. SPM and lon, were constructed first. After replacement of whole SPI1 with a chloramphenicol gene cassette, this mutation was transferred to a new recipient by P22 phage mediated transduction. Following the transduction, the chloramphenicol resistance gene was excised by flipase encoded by transiently introduced pCP20 plasmid. The strain with a total deletion of SPI1 was transduced with P22 phage grown on Salmonella enterica /on::Cm.
• the vaccination with Salmonella enterica CAPM 6449 protected chickens against the infection with the wild type Salmonella enterica serovar Enteritidis since Salmonella counts were 10 to 100 times lower in the vaccinated than in the non-vaccinated chickens. Even in the cases when the presence of Salmonella was only qualitatively determined, the numbers of Salmonella positive chickens in the vaccinated chickens were lower than in the non-vaccinated controls.
• Data in the table show either log CFU/g) or number of positive out of total number of tested chickens.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Medicinal Chemistry (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=47748361

Family Applications (1)

Country Status (4)

• 2011
  • 2011-12-27 CZ CZ2011-887A patent/CZ307299B6/cs not_active IP Right Cessation
• 2012
  • 2012-12-19 WO PCT/CZ2012/000138 patent/WO2013097838A1/en not_active Ceased
  • 2012-12-19 RU RU2014125037/10A patent/RU2014125037A/ru not_active Application Discontinuation
  • 2012-12-19 EP EP12826596.4A patent/EP2841094A1/en not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events